BioMerieux (BMXMF) Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research upgraded shares of BioMerieux (OTCMKTS:BMXMF) from a hold rating to a buy rating in a report issued on Wednesday morning. The brokerage currently has $91.00 target price on the stock.
According to Zacks, “bioMérieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioMérieux S.A. is based in Marcy L Etoile, France. “
Shares of BMXMF opened at $81.44 on Wednesday. BioMerieux has a fifty-two week low of $60.50 and a fifty-two week high of $95.05. The company has a market capitalization of $9.64 billion and a PE ratio of 35.72. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.99 and a quick ratio of 1.30.
bioMérieux SA provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involves culturing biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as measures the specific biomarkers of various pathologies, such as metabolic, hormonal, infectious, etc.
Featured Story: What is the yield curve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioMerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMerieux and related companies with MarketBeat.com's FREE daily email newsletter.